FEED Business Worldwide - September, 2011
EPO rules in Danisco's favour, Novozymes appeals decision
The European Patent Office (EPO) sided with DuPont's Danisco unit, ruling that a Novozymes patent is invalid. Previously, Novozymes, which was awarded the patent in 2009, last month won an injunction against a Danisco product which it claimed infringed on the patent.
According to Soonhee Jang, Danisco's chief intellectual property counsel, "Danisco has strongly maintained that the patent is invalid and that Danisco's products do not infringe. We are gratified and very pleased with this decision."
Because Novozymes promptly appealed the EPO's, the patent will stand as granted until the patent board rules on this challenge to its ruling. Annegrethe Jakobsen, a spokeswoman for Bagsvaerd, Denmark-based Novozymes stated, "We still have a strong confidence in the validity of the patent,"
In the United States, these two companies remain deadlocked in a patent court case on a biofuel manufacturing catalyst.
Pfizer re-evaluates its animal health and nutrition strategy
Pfizer Inc. announced that it is exploring strategic alternatives for its animal health and nutrition businesses.
Options Pfizer is considering includes a full or partial separation of each of these businesses from Pfizer through a spin-off, sale or other transaction. Given the separate and distinct nature of Animal Health and Nutrition, the company may pursue a different strategic alternative and separate them into two different business segments.
"Both Animal Health and Nutrition are strong businesses with attractive customer bases and solid fundamentals, but distinct enough from our core businesses that their value may be best maximised outside the company," said Ian Read, president and chief executive officer, Pfizer. "In exploring these alternatives, we can determine what options will best drive their future growth opportunities and expansion, and enable shareholders to potentially realise higher value for these businesses."
Pfizer has engaged JP Morgan in connection with the evaluation of strategic alternatives for its animal health business. Morgan Stanley and Centerview Partners' advisory business is evaluating strategic alternatives for its nutrition business.
Although the timeline for each evaluation may differ, Pfizer expects to complete any transactions that may result from these evaluations in 12 to up to 24 months. It does not anticipate making any further announcements regarding strategic alternatives for its Animal Health and Nutrition line until sometime in 2012.
Gold Coin acquires shrimp genetics company SyAqua
Animal nutrition and feed milling group Gold Coin has announced that their full acquisition of shrimp genetics and biotechnology company SyAqua.
Dr Thomas Gitterle, previously Head of the Genetic and Breeding Department at CENIACUA (Colombia) and Scientific Advisor to the AKVAFORSK Genetic Center (Norway), was appointed technical director of SyAqua in charge of genetic improvement and development.
Dr Gitterle will also oversee a number of research initiatives and activities, including a Nutrigenomics project in Singapore and a research programme in Indonesia for IMNV.
Tycho Vos, the newly appointed managing director to the SyAqua Group, said, "In the last 10 years, SyAqua has developed a unique and strong genetics and breeding programme, targeting improvements in growth performance, robustness, and resistance to diseases."
Gold Coin CEO JC Filipi added that, "The key objective of this strategic acquisition is to offer an alternative to Asian shrimp farmers, combining technical and commercial synergies between nutrition and genetics to enhance shrimp production performances, and therefore farmers' profitability."
SyAqua's main Asian Genetic Nuclei units are located in Thailand and Singapore. SyAqua operates commercial hatcheries producing post larvae and Nauplii in Thailand and Indonesia, and exports commercial broodstock throughout the ASEAN region.
Gold Coin is a pioneer in Asian animal and shrimp nutrition, building its first aqua feed mill in Malaysia in the early 1990s. It produces both livestock and aqua feed and has a presence in eight Asian countries.
Amlan selects Elanco Animal Health as its Brazilian distributor
Amlan International, the manufacturer of Calibrin enterosorbents, announced that it has signed a distribution agreement with Elanco Animal Health to distribute its products in Brazil.
Elanco Animal Health was founded in 1953 and is a global, innovation-driven company that develops and markets products to improve animal health and meat production in more than 75 countries. As its sole distributor in Brazil, Elanco will market, sell and promote Calibrin and other products offered by Amlan International.
Vice President of Amlan International, Ron Cravens said, "We are very pleased with this agreement. Our new relationship with Elanco helps us broaden our market access to all customers in the swine, poultry and dairy production segment, and capitalise on Elanco's expertise and knowledge of disease management."
The above are excerpts, full versions are only available in FEED Business Worldwide. For subscriptions enquiries, e-mail email@example.com